Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylpropanolamine hydrochloride.

D M Williams1

  • 1Division of Pharmacy Practice, School of Pharmacy, University of North Carolina, Chapel Hill 27599-7360.

American Pharmacy
|October 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical Combination of ATLAS Run 2 Searches for Charginos and Neutralinos at the LHC.

Physical review letters·2024
Same author

Combination of Measurements of the Top Quark Mass from Data Collected by the ATLAS and CMS Experiments at sqrt[s]=7 and 8 TeV.

Physical review letters·2024
Same author

Combination of Searches for Resonant Higgs Boson Pair Production Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2024
Same author

Search for Nearly Mass-Degenerate Higgsinos Using Low-Momentum Mildly Displaced Tracks in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2024
Same author

Azimuthal Angle Correlations of Muons Produced via Heavy-Flavor Decays in 5.02 TeV Pb+Pb and pp Collisions with the ATLAS Detector.

Physical review letters·2024
Same author

Study of High-Transverse-Momentum Higgs Boson Production in Association with a Vector Boson in the qqbb Final State with the ATLAS Detector.

Physical review letters·2024
Same journal

Genetically engineered vaccines.

American pharmacy·1995
Same journal

GAO report on need for a third class: 'prove it'.

American pharmacy·1995
Same journal

Treatment of community-acquired urinary tract infections.

American pharmacy·1995
Same journal

Liability and the changing role of pharmacists.

American pharmacy·1995
Same journal

Dispensing errors and counseling in community practice.

American pharmacy·1995
Same journal

Avoiding liability problems. American Pharmaceutical Association.

American pharmacy·1995
See all related articles

Phenylpropanolamine is safe for short-term weight control when used as directed. Pharmacists play a key role in counseling patients on appropriate use and potential side effects to prevent misuse.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Public Health

Background:

  • Phenylpropanolamine (PPA) is recognized by the FDA advisory review panel for its efficacy in short-term weight management.
  • The established maximum daily dosage for PPA in weight control is 75 mg.
  • Serious adverse events associated with PPA are infrequent when used at recommended doses in patients without significant risk factors.

Purpose of the Study:

  • To review the safety and efficacy of Phenylpropanolamine for short-term weight control.
  • To outline the role of pharmacists in patient counseling regarding PPA use.
  • To inform healthcare providers and patients about potential risks and management strategies.

Main Methods:

  • Review of FDA advisory panel classifications and recommendations.

Related Experiment Videos

  • Analysis of PPA dosage and risk factors for adverse events.
  • Emphasis on patient counseling protocols for safe and effective use.

    • Main Results:

    • Phenylpropanolamine is considered generally safe and effective for short-term weight control within the 75 mg daily dose limit.
    • Adverse reactions are infrequent in patients without contraindications when adhering to recommended dosages.
    • Patient counseling is crucial for preventing misuse and ensuring adherence to short-term treatment (≤12 weeks).

    Conclusions:

    • Pharmacists are vital in educating patients about the appropriate, short-term application of Phenylpropanolamine in weight-reduction programs.
    • Patients must be informed about recognizing and reporting signs of serious adverse reactions to PPA.
    • Discontinuation of PPA is advised upon the appearance of any adverse reactions.